Beta Bionics, Inc. (BBNX)
| Market Cap | 975.35M-18.4% |
| Revenue (ttm) | 119.01M |
| Net Income | -72.97M |
| EPS | -1.64 |
| Shares Out | 53.95M |
| PE Ratio | n/a |
| Forward PE | -8.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,531,154 |
| Open | 18.91 |
| Previous Close | 18.63 |
| Day's Range | 17.93 - 19.11 |
| 52-Week Range | 8.80 - 32.71 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 23.80(+31.64%) |
| Earnings Date | Oct 27, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About BBNX
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$BBNX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BBNX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BBNX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BBNX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BBNX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| DME Channel | $20.41M | 63.76% |
| PBP Channel | $11.60M | 36.24% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BBNX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BBNX from public contracts
Source: USAspending.gov
BBNX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BBNX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score